Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433999 · ClinicalTrials.gov registry record · Phase 2
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
A Phase 2 study, sponsored by Priovant Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT06433999: Completed Phase 2 study, sponsored by Priovant Therapeutics.
NCT06433999 is a Phase 2 study that has completed, run by Priovant Therapeutics. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06433999, a Phase 2 study, has completed, sponsored by Priovant Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg orally (PO) QD for 12 weeks.
Interventions
- DRUG Brepocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2025-02-28 |
| Phase | Phase 2 |
What the finished NCT06433999 record still lists
NCT06433999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Brepocitinib is the first listed.
NCT06433999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06433999 about?
NCT06433999 is a clinical study titled "A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis". This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg...
What is the current status of trial NCT06433999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2024-08-28. Estimated completion is 2025-02-28.
What interventions are being tested in trial NCT06433999?
The interventions under investigation include: Brepocitinib (DRUG).
Who is sponsoring clinical trial NCT06433999?
This trial is sponsored by Priovant Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06433999's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI